Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MT-201-GBM |
Synonyms | |
Therapy Description |
MT-201-GBM is a vaccine comprised of autologous monocytes containing mRNA encoding a fusion protein of pp65 and lysosome-associated membrane protein (LAMP), which may lead to an increased T-cell response against tumor cells expressing pp65 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MT-201-GBM | MT 201-GBM|MT201-GBM | MT-201-GBM is a vaccine comprised of autologous monocytes containing mRNA encoding a fusion protein of pp65 and lysosome-associated membrane protein (LAMP), which may lead to an increased T-cell response against tumor cells expressing pp65 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04741984 | Phase I | MT-201-GBM | Monocyte Antigen Carrier Cells for Newly Diagnosed GBM | Withdrawn | 0 |